Alogliptin (Nesina) for Type 2 Diabetes
May 27, 2013 (Issue: 1417)
The FDA has approved the dipeptidyl peptidase-4
(DPP-4) inhibitor alogliptin (Nesina – Takeda) for treatment
of type 2 diabetes. In addition to the single-ingredient
product, the FDA also approved fixed-dose
combinations of alogliptin/metformin...more
1. Drugs for type 2 diabetes. Treat Guidel Med Lett 2011; 9:47.
2. What comes after metformin for type 2 diabetes. Med Lett Drugs Ther 2012; 54:58.
3. MA Nauck et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63:46.
4. RA DeFronzo et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97:1615.
5. RE Pratley et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11:167.
6. RE Pratley et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009; 25:2361.
7. E Bosi et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 2011; 13:1088.
8. J Rosenstock et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1c) without causing weight gain or increased hypoglycemia. Diabetes Obes Metab 2009; 11:1145.
9. Linagliptin (Tradjenta) – a new DDP-4 inhibitor for type 2 diabetes. Med Lett Drugs Ther 2011; 53:49.
10. Saxagliptin (Onglyza) for type 2 diabetes. Med Lett Drugs Ther 2009; 51:85.
11. Sitagliptin (Januvia) for type 2 diabetes. Med Lett Drugs Ther 2007; 49:1.
12. S Singh et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173:534.
13. PC Butler et al. A critical analysis of the clinical use of incretin-based therapies: are GLP-1 therapies safe? Diabetes Care 2013 May 6 (epub).
14. T Stulc and A Sedo. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010; 88:125.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
